TW202333658A - 包含腎上腺素之新穎醫藥組合物 - Google Patents

包含腎上腺素之新穎醫藥組合物 Download PDF

Info

Publication number
TW202333658A
TW202333658A TW111145222A TW111145222A TW202333658A TW 202333658 A TW202333658 A TW 202333658A TW 111145222 A TW111145222 A TW 111145222A TW 111145222 A TW111145222 A TW 111145222A TW 202333658 A TW202333658 A TW 202333658A
Authority
TW
Taiwan
Prior art keywords
composition
compositions
epinephrine
powder
reservoir
Prior art date
Application number
TW111145222A
Other languages
English (en)
Chinese (zh)
Inventor
約納斯 塞夫馬克
羅伯特 勒恩
Original Assignee
瑞典商奥瑞克索股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2117015.4A external-priority patent/GB202117015D0/en
Priority claimed from GBGB2117016.2A external-priority patent/GB202117016D0/en
Application filed by 瑞典商奥瑞克索股份公司 filed Critical 瑞典商奥瑞克索股份公司
Publication of TW202333658A publication Critical patent/TW202333658A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00—Ancillary equipment
    • A61M2209/06—Packaging for specific medical equipment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111145222A 2021-11-25 2022-11-25 包含腎上腺素之新穎醫藥組合物 TW202333658A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB2117015.4 2021-11-25
GB2117016.2 2021-11-25
GBGB2117015.4A GB202117015D0 (en) 2021-11-25 2021-11-25 New pharmaceutical composition
GBGB2117016.2A GB202117016D0 (en) 2021-11-25 2021-11-25 New pharmaceutical device

Publications (1)

Publication Number Publication Date
TW202333658A true TW202333658A (zh) 2023-09-01

Family

ID=84367174

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111145222A TW202333658A (zh) 2021-11-25 2022-11-25 包含腎上腺素之新穎醫藥組合物

Country Status (12)

Country Link
US (2) US11957647B2 (https=)
EP (1) EP4236921A1 (https=)
JP (1) JP2024541470A (https=)
KR (1) KR20240103005A (https=)
AR (1) AR127780A1 (https=)
AU (1) AU2022395920A1 (https=)
CA (1) CA3238850A1 (https=)
IL (1) IL313016A (https=)
MX (1) MX2024006188A (https=)
TW (1) TW202333658A (https=)
WO (1) WO2023094826A1 (https=)
ZA (1) ZA202403890B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3962455T (pt) 2020-05-18 2022-10-13 Orexo Ab Nova composição farmacêutica para entrega de fármacos
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
TW202502309A (zh) 2023-05-31 2025-01-16 瑞典商奥瑞克索股份公司 包含腎上腺素激導性受體調節劑的噴霧乾燥之組合物
US20260108686A1 (en) * 2024-10-21 2026-04-23 Belhaven BioPharma Inc. Compositions, devices, and methods for intranasal delivery of dry powder epinephrine

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1411A (en) 1839-11-16 Improvement in the machine for turning the heads of wood screws and rivets
US2005A (en) 1841-03-16 Improvement in the manner of constructing molds for casting butt-hinges
BE759520A (fr) 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions d'aspirine
US5082669A (en) 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
SE8904296D0 (sv) 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
ATE196427T1 (de) 1993-12-06 2000-10-15 Takeda Chemical Industries Ltd Zusammensetzung mit verbesserter wasserlöslichkeit, enthaltend eine wasserunlösliche oder an wasser schwerunlösliche verbindung
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
CN1106888C (zh) 1998-03-10 2003-04-30 瓦卢瓦股份有限公司 容器、容器的灌注方法及容器中流体制品的分配装置
JP3422775B2 (ja) 1998-07-08 2003-06-30 キリン−アムジエン・インコーポレーテツド 高分子医薬品含有粉末状経粘膜投与製剤
JP2000178184A (ja) 1998-12-17 2000-06-27 Lion Corp 粒状組成物、錠剤及び粒状組成物の製造方法
GB9908921D0 (en) 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
GB0003782D0 (en) 2000-02-17 2000-04-05 Dumex Ltd As Process
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
KR20010107754A (ko) 2000-05-26 2001-12-07 민경윤 경구투여용 속용정의 제조 방법
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
IN192750B (https=) 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US6443152B1 (en) 2001-01-12 2002-09-03 Becton Dickinson And Company Medicament respiratory delivery device
LU90825B1 (en) 2001-09-06 2003-03-07 Iee Sarl Method for the determination of one or more parameters of a seat passenger
ITMI20012174A1 (it) 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
GB0201367D0 (en) 2002-01-22 2002-03-13 Ml Lab Plc Composition
AU2006207868A1 (en) * 2002-03-20 2006-09-28 Alkermes, Inc. Method and apparatus for producing dry particles
SI1531794T1 (sl) 2002-06-28 2017-12-29 Civitas Therapeteutics, Inc. Epinefrin za vdihavanje
WO2004054511A2 (en) 2002-12-13 2004-07-01 The Regents Of The University Of California Analgesic combination comprising nalbuphine
EP2343045A3 (en) 2003-02-24 2011-09-21 Pharmaceutical Productions Inc. Transmucosal drug delivery system
JP4739217B2 (ja) 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
US7954491B2 (en) 2003-06-13 2011-06-07 Civitas Therapeutics, Inc. Low dose pharmaceutical powders for inhalations
CN100471497C (zh) 2003-06-25 2009-03-25 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻粉剂
US20050042178A1 (en) 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
CN100515511C (zh) 2003-10-09 2009-07-22 株式会社;生命科学活效 鼻腔用粉状药剂施药装置
WO2005044186A2 (en) 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
EP1701706A2 (en) 2003-12-29 2006-09-20 Alza Corporation Novel drug compositions and dosage forms
CN1640402A (zh) 2004-01-02 2005-07-20 广东奇方药业有限公司 一种稳定的纳洛酮粉针剂
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
CN1615867A (zh) 2004-10-22 2005-05-18 北京阳光润禾科技有限公司 注射用盐酸纳洛酮冻干粉针制剂
WO2006101536A1 (en) 2004-11-04 2006-09-28 Akina, Inc. Fast-melting tablets having taste-masking and sustained release properties
CN1781479B (zh) 2004-12-02 2010-06-30 和记黄埔医药企业有限公司 一种马蔺子素分散体系及其制备方法
US20080317863A1 (en) 2005-02-10 2008-12-25 Christer Nystrom Pharmaceutical Compositions Useful in the Transmucosal Administration of Drugs
KR101233235B1 (ko) 2005-08-26 2013-02-15 에스케이케미칼주식회사 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법
US20070202163A1 (en) 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
CN1939358A (zh) 2005-09-30 2007-04-04 江西本草天工科技有限责任公司 肿节风分散片
CN1813739A (zh) 2005-11-25 2006-08-09 王颖 一种注射用盐酸纳美芬冻干粉针制剂
CA2640165A1 (en) 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
WO2007096906A2 (en) 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
US20100226979A1 (en) 2006-03-21 2010-09-09 Jubilant Organosys Limited Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate
CN101460150B (zh) 2006-03-31 2014-02-12 鲁比康研究私人有限公司 用于口腔崩解片剂的可直接压片复合物
PL2061427T3 (pl) 2006-09-15 2011-12-30 Echo Pharmaceuticals Bv Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania
US20080269347A1 (en) 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
JP2010515753A (ja) 2007-01-10 2010-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 肺内送達用免疫抑制剤組成物の送達の増強
WO2009040595A1 (en) 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
CN102083467B (zh) 2008-03-11 2013-12-25 Aska制药株式会社 固体分散体及其药物组合物、以及它们的制备方法
US20090246256A1 (en) 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
US20090264530A1 (en) 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
US20110294864A1 (en) 2009-01-13 2011-12-01 Universiteit Gent Aqueous coacervate compositions suitable for making powders and water-soluble formulations of biologically-active agents
ES2661215T3 (es) 2009-05-20 2018-03-28 Aeras Composiciones víricas; inmunógenas; secadas por pulverización; estables
PL3111927T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
DK2480197T3 (en) 2009-09-25 2016-01-25 Reddys Lab Ltd Dr Compositions containing triptanforbindelser
RU2013113627A (ru) 2010-08-27 2014-10-10 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
CN103200938B (zh) 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
MX2013003522A (es) 2010-10-01 2013-05-22 Cipla Ltd Composicion farmaceutica.
CN107028900A (zh) 2010-12-02 2017-08-11 艾戴尔医药公司 快速分散颗粒、口腔崩解片以及方法
DK2675301T3 (en) 2011-02-18 2019-03-25 Biolingus Ip Llc PROCEDURE FOR PRODUCING PRODUCTS CONTAINING STABILIZED ACTIVE SUBSTANCES
MY194947A (en) 2011-05-13 2022-12-27 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
BR112014028431B1 (pt) 2012-05-11 2022-01-11 Activus Pharma Co., Ltd Nanopó de composto orgânico, método para produzir o mesmo e suspensão
EP2861224A4 (en) 2012-06-15 2015-11-18 Univ Nova Southeastern EPINEPHRINNANOPARTICLES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE USE THEREOF FOR TREATING SUFFERING SUFFERING TO EPINEPHRIN
US9789071B2 (en) * 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
EP3248642B1 (en) 2012-06-28 2020-04-08 The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services Nasal dry powder delivery system for vaccines and other treatment agents
FR3007992B1 (fr) 2013-07-05 2018-01-26 Aptar France Sas Dispositif de distribution de produit fluide ou pulverulent.
MX2016002705A (es) 2013-09-03 2016-09-06 G2B Pharma Inc Formulacion intranasal para el tratamiento por reanimacion cardiopulmonar (rcp), mantenimiento cardiaco vital (cls), de anafilaxia y/o reacciones anafilactoides.
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
WO2015095389A1 (en) 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
US20190008759A1 (en) 2014-07-03 2019-01-10 Darren Rubin Safer and more effective methods of transmucosal delivery for raising blood pressure and stimulating the body
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3174534A1 (en) 2014-08-01 2017-06-07 KRKA, d.d., Novo mesto Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
WO2016044813A1 (en) 2014-09-18 2016-03-24 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
WO2016055544A1 (en) 2014-10-08 2016-04-14 Eratech S.R.L. Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
EP3220893B1 (en) 2014-11-14 2023-06-07 Asoltech Srl Composition based on coq10
EP3025705B8 (en) 2014-11-25 2018-11-28 Sanofi Ilaç Sanayi ve Ticaret Anonim Sirketi Stable ivabradine formulations
CN104547220A (zh) 2014-12-30 2015-04-29 陈宏� 一种治疗儿童视觉疲劳的中药组合物及其制剂
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
BR112017014994B1 (pt) 2015-02-17 2023-12-19 Eli Lilly And Company Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
AU2015390471A1 (en) 2015-04-08 2017-11-09 John KLASSEN Pharmaceutical compositions of polyanionic and non-ionic cyclodextrin-based dendrimers and uses thereof
HK1251998A1 (zh) 2015-05-01 2019-05-10 Civitas Therapeutics, Inc. 佐米曲普坦肺部给药粉
US10039710B2 (en) 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
AU2017210319A1 (en) 2016-01-20 2018-08-23 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
ITUB20161027A1 (it) 2016-02-24 2017-08-24 Altergon Sa Preparazioni farmaceutiche oromucosali ad elevata biodisponibilita’ a base di ciclodestrina e sucralosio
WO2017158439A1 (en) 2016-03-16 2017-09-21 Omegatri As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
US20170312226A1 (en) 2016-04-28 2017-11-02 Ascent Pharmaceuticals, Inc. Pharmaceutical dosage forms
US11903951B2 (en) 2016-06-03 2024-02-20 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
WO2017218918A1 (en) 2016-06-17 2017-12-21 Ys Pharmtech Stabilization of epinephrine formulations
WO2018009532A1 (en) 2016-07-06 2018-01-11 Mccormick & Company, Incorporated Natural encapsulation flavor products
EP3493789A2 (en) 2016-08-05 2019-06-12 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
JP2020500081A (ja) 2016-09-28 2020-01-09 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． オピオイドを送達する経皮薬剤送達装置
WO2018064672A1 (en) 2016-09-30 2018-04-05 Opiant Pharmaceuticals, Inc. Treatment with intranasal naloxone
US20180092839A1 (en) 2016-10-03 2018-04-05 Lance L. Gooberman Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
CA3043028A1 (en) 2016-11-09 2018-05-17 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
IL312012A (en) 2016-11-18 2024-06-01 Opiant Pharmaceuticals Inc Compositions and methods for the treatment of opioid overdose
WO2018148382A1 (en) 2017-02-10 2018-08-16 Mucodel Pharma Llc Chemically stable compositions of a pharmaceutical active agent in a multi-chambered delivery system for mucosal delivery
CN111050760A (zh) 2017-04-17 2020-04-21 希克玛制药美国公司 肾上腺素喷雾制剂
EP3668490A4 (en) 2017-08-20 2021-06-09 Formulex Pharma Innovations Ltd. Dry powder compositions for intranasal delivery
US20180193332A1 (en) 2017-10-09 2018-07-12 Adapt Pharma Operations Limited Low-temperature stable opioid antagonist solutions
WO2019139865A1 (en) 2018-01-10 2019-07-18 Insys Development Company. Inc. Methods of stabilizing epinephrine
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
EP3806827A4 (en) 2018-06-13 2022-03-23 Hikma Pharmaceuticals USA Inc. EPINEPHRINE SPRAY FORMULATIONS
US20230014352A1 (en) 2019-03-29 2023-01-19 The Regents Of The University Of California Inhaled statins as bronchodilators to improve lung function in respiratory diseases
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) * 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
FR3098420B1 (fr) 2019-07-10 2021-07-09 Aptar France Sas Dispositif de distribution nasale de poudre
US11400045B2 (en) 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine
PT3962455T (pt) * 2020-05-18 2022-10-13 Orexo Ab Nova composição farmacêutica para entrega de fármacos
FR3121047B1 (fr) 2021-03-29 2023-07-14 Aptar France Sas Dispositif de distribution nasale de poudre
US11617716B2 (en) 2021-06-10 2023-04-04 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device

Also Published As

Publication number Publication date
MX2024006188A (es) 2024-06-11
ZA202403890B (en) 2025-10-29
AR127780A1 (es) 2024-02-28
JP2024541470A (ja) 2024-11-08
WO2023094826A1 (en) 2023-06-01
KR20240103005A (ko) 2024-07-03
IL313016A (en) 2024-07-01
US20230355552A1 (en) 2023-11-09
US12472154B2 (en) 2025-11-18
US20250041243A1 (en) 2025-02-06
AU2022395920A1 (en) 2024-05-30
EP4236921A1 (en) 2023-09-06
CA3238850A1 (en) 2023-06-01
US11957647B2 (en) 2024-04-16

Similar Documents

Publication Publication Date Title
JP7753183B2 (ja) 経鼻送達用の医薬組成物
EP3962455B1 (en) New pharmaceutical composition for drug delivery
US12472154B2 (en) Pharmaceutical composition comprising adrenaline
US12303472B2 (en) Pharmaceutical device for use in intranasal administration
US11883392B2 (en) Pharmaceutical composition for nasal delivery
KR20260016535A (ko) 아드레날린 수용체 조절제를 포함하는 분무 건조 조성물
KR20260019501A (ko) Cgrp 수용체 길항제를 포함하는 분무 건조 조성물
WO2023094817A1 (en) Pharmaceutical composition comprising atropine
HK40071082B (en) New pharmaceutical composition for drug delivery
HK40071082A (en) New pharmaceutical composition for drug delivery